Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).
Conditions
Interventions
BMB-101
Locations
5
Australia
The Prince of Wales Hospital
Randwick, New South Wales, Australia
Royal Brisbane and Womans Hospital
Herston, Queensland, Australia
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Start Date
December 5, 2024
Primary Completion Date
September 15, 2025
Completion Date
November 30, 2025
Last Updated
August 12, 2025
NCT06315322
NCT06872125
NCT05419492
NCT04462770
NCT06598449
NCT06504511
Lead Sponsor
Bright Minds Biosciences Pty Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions